Physician profile
Andrew Mastro
NPI 1427585132
$418,993.48
in general payments reported to CMS, 2019-2025
32 companies · $199K in 2025
The $199K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,773 · 2022: $5,367 · 2023: $50K · 2024: $163K · 2025: $199K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Consulting Fee: $139K · Travel and Lodging: $67K · Food and Beverage: $31K · Honoraria: $3,033 · Education: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,282.51 |
| Consulting Fee | $139,177.10 |
| Travel and Lodging | $67,098.11 |
| Food and Beverage | $30,759.59 |
| Honoraria | $3,033.11 |
| Education | $503.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66,331.27 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $63,918.85 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $53,003.83 | 2022-2024 | Vtama, Tapinarof |
| Abbvie INC. | $40,447.30 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $37,361.55 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $27,886.87 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $23,428.89 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Janssen Biotech, INC. | $22,831.55 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $15,078.53 | 2022-2025 | Opzelura |
| Pfizer INC. | $14,110.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $11,235.17 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $11,163.80 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Organon LLC | $9,550.87 | 2024-2025 | Vtama, Nexplanon |
| Ucb, INC. | $6,209.96 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $4,864.29 | 2021-2025 | Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,365.59 | 2021-2025 | |
| Eli Lilly and Company | $3,878.88 | 2022-2024 | Olumiant |
| Sanofi US Services INC. | $823.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $450.23 | 2023-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $423.49 | 2022-2025 | Siliq, Jublia, Cabtreo |
| Sanofi-Aventis U.S. LLC | $389.36 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $350.00 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $188.82 | 2021 | |
| Mayne Pharma Commercial LLC | $135.43 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $100.00 | 2021 | |
| Biofrontera INC. | $92.49 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $86.85 | 2025 | Sofdra |
| Journey Medical Corporation | $81.08 | 2022-2025 | |
| Strata Skin Sciences, INC. | $73.90 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $57.95 | 2025 | Ycanth |
| Almirall LLC | $49.68 | 2023-2025 | Klisyri, Seysara |
| Dermira, INC. | $23.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.